1-6 of 6
Abbie Ba-Mancini
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Cost Offsets in the Treatment Journeys of Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Free
Sikander Ailawadhi, Maral DerSarkissian, PhD, Mei Sheng Duh, MPH, ScD, Marie-Hélène Lafeuille, MA, George Posner, BA, Stephen Ralston, PhD, Erin Zagadailov, PharmD, MS, Abbie Ba-Mancini, MSc, MBA, Robert M Rifkin, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5599.
https://doi.org/10.1182/blood.V130.Suppl_1.5599.5599
Published: 2017
Journal Articles

Comparable Outcomes With Bortezomib-Cyclophosphamide-Dexamethasone (VCD) and Bortezomib-Lenalidomide-Dexamethasone (VRD) For Initial Treatment Of Newly Diagnosed Multiple Myeloma (MM)

Free
Shaji K Kumar, MD, Ann E Engebretson, Francis K Buadi, MD, Martha Q Lacy, MD, Angela Dispenzieri, MD, Mei Sheng Duh, MPH, Sc.D, Marie-Hélène Lafeuille, MA, Patrick Lefebvre, MA, B.Sc, Wendy Y Cheng, MPH, MPhil, Katherine Dea, MA, Mark Yap, BSN, RN, Shanmugapriya Saravanan, MS, Iwen Pan, Ph.D, Debra Rembert, RN, MSN, NP, Rahul Dhanda, PhD, Liviu Niculescu, MD, Abbie Ba-Mancini, BS MBA, Esprit Ma, MPH, Maureen Quick, RN, MS, OCN, S. Vincent Rajkumar, MD
Journal: Blood
Blood (2013) 122 (21): 3178.
https://doi.org/10.1182/blood.V122.21.3178.3178
Published: 2013
Journal Articles

Impact Of Route Of Bortezomib (B) Administration On Dose Intensity and Time To Dose Reduction In Previously Untreated Patients (Pts) With Multiple Myeloma (MM)

Free
Robert M Rifkin, MD, FACP, Clara Chen, MS, Rahul Dhanda, Ph.D, Debra Rembert, RN, MSN, NP, Abbie Ba-Mancini, BS MBA, Esprit Ma, MPH, Yanyan Zhu, Ph.D, MPH, Edward Dow, MD, Liviu Niculescu, MD
Journal: Blood
Blood (2013) 122 (21): 1941.
https://doi.org/10.1182/blood.V122.21.1941.1941
Published: 2013
Journal Articles

Efficacy and Safety Of Three Bortezomib-Based Induction and Maintenance Regimens In Previously Untreated, Transplant-Ineligible Multiple Myeloma (MM) Patients (Pts): Final Results From The Randomized, Phase 3b, US Community-Based UPFRONT Study (NCT00507416)

Free
Ruben Niesvizky, MD, Ian Flinn, MD, PhD, Robert M. Rifkin, MD, James Essell, MD, Yousuf Gaffar, MD, Thomas Warr, MD, Rachel Neuwirth, Ph.D, Abbie Ba-Mancini, BS MBA, Yanyan Zhu, Ph.D, MPH, Liviu Niculescu, MD, James Reeves, MD
Journal: Blood
Blood (2013) 122 (21): 1966.
https://doi.org/10.1182/blood.V122.21.1966.1966
Published: 2013
Journal Articles

Meta-Analysis of the Efficacy and Safety of Bortezomib Retreatment in Patients with Multiple Myeloma (MM)

Free
Kevin B Knopf, MD, Mei Sheng Duh, ScD, MPH, Marie-Hélène Lafeuille, MA, Jonathan Gravel, Patrick Lefebvre, MA, Liviu Niculescu, Abbie Ba-Mancini, BS, MBA, Esprit Ma, Hongliang Shi, MS, Raymond L. Comenzo, MD
Journal: Blood
Blood (2012) 120 (21): 1863.
https://doi.org/10.1182/blood.V120.21.1863.1863
Published: 2012
Journal Articles

The Cost-Effectiveness of Bortezomib Plus Melphalan and Prednisone Versus Lenalidomide Plus Melphalan and Prednisone with Continuous Lenalidomide Maintenance Treatment for the Initial Treatment of Multiple Myeloma In the United States

Free
Si-Tien Wang, MS, Hui Huang, PhD, MBA, Abbie Ba-Mancini, BS, MBA, Hongliang Shi, MS, Kristina Chen, MS, Caroline Korves, ScD, Ravinder Dhawan, PhD, Andrew Cakana, FRCPath, MD, Helgi van de Velde, Dixie-Lee W. Esseltine, MD, FRCPC, Mei S. Duh, ScD, MPH
Journal: Blood
Blood (2010) 116 (21): 2563.
https://doi.org/10.1182/blood.V116.21.2563.2563
Published: 2010